Genome-wide analysis of the hypoxia-related DNA methylation-driven genes in lung adenocarcinoma progression

Hongxia Li¹, Li Tong¹, Hong Tao¹, Zhe Liu¹*

¹ Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China

*Corresponding author: Zhe Liu, MD & PhD, Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, No. 1 Beiguandajie, Tongzhou District, Beijing, 101149, China. E-mail: zheliu_lza@163.com

Running title: The hypoxia-related key genes in LUAD
Abstract

Lung adenocarcinoma (LUAD) is a common type of lung cancer with high incidence and poor prognosis. Hypoxia and DNA methylation play important regulatory roles in cancer progression. The purpose of this study was to explore the relationship between hypoxia and DNA methylation, and to identify key genes for hypoxia-regulated LUAD progression. Hypoxia score (HS) was calculated using the GSVA algorithm. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment and protein–protein interaction (PPI) analysis were performed using clusterProfile package, STRING database and Cytoscape software. Kaplan-Meier curves of overall survival (OS) and disease-free survival (DFS) were drawn using R software. Smoking status and cancer stages were significantly associated with LUAD hypoxia, and hypoxia is a poor prognostic factor for LUAD. Compared with HS-low group, 1803 aberrantly methylated DEGs were identified in HS-high group. KEGG analysis showed that the 1803 genes were enriched in the metabolic pathways associated with hypoxia stress, angiogenesis, and cancer progression. FAM20C, MYLIP and COL7A1 were identified as the hypoxia-related key genes in LUAD progression, which were regulated by DNA methylation. Hypoxia in LUAD tumor cells led to changes in DNA methylation patterns. In-depth study of the relationship between hypoxia and DNA methylation is helpful to elucidate the mechanism of tumorigenesis, and provide new ideas for LUAD treatment.

Keywords: Lung adenocarcinoma; Hypoxia; DNA methylation; hypoxia-related gene
Introduction

Non-small cell lung cancer is a common malignant tumor worldwide, accounting for almost 85% of the total number of lung cancers[1]. Lung adenocarcinoma (LUAD) is an important pathological type of non-small cell lung cancer, and the incidence of LUAD is increasing year by year. Lack of early diagnosis system and effective treatment, tumor recurrence, and chemoresistance are the main problems in the diagnosis and treatment of lung cancer[2, 3]. Therefore, further exploring the biological mechanism of lung cancer progression, establishing an early detection system, identifying key therapeutic targets, and overcoming chemotherapy resistance are the keys to improving the outcome of patients with NSCLC.

Hypoxia is a characteristic microenvironment of solid tumors, and is closely related to the occurrence and development of tumors[4-6]. The hypoxic regions in human malignant parenchymal tumors have important effects on tumor biological behavior[7]. Hypoxic tumor cells promote angiogenesis by altering their metabolism to ensure tumor cell survival. In addition, hypoxia can also induce changes in the tumor microenvironment[7, 8]. Hypoxia induces the expression of matrix metalloproteinases and other protease genes through hypoxia-inducible factors (HIFs), which leads to degradation of the matrix surrounding the tumor and provides a "green" channel for tumor metastasis[9]. Furthermore, hypoxia microenvironment can also affect the sensitivity of tumor cells to treatment[10]. However, the role of the hypoxia in the development of LUAD is still unclear.

In addition to genetic abnormalities, tumor cells are also regulated by epigenetic mechanisms such as local hypermethylation of CpG islands and extensive hypomethylation of the genome[11, 12]. However, the mechanism that cause changes in DNA methylation patterns remains unclear. Many researches have confirmed that epigenetic changes in many genes are closely related to tumorigenesis, prognosis and drug resistance[13-15]. DNA methylation is negatively correlated with gene expression, and regulates gene function by affecting the spatial conformation of chromatin. In addition, DNA methylation can inhibit gene expression by directly inhibiting polymerases activities[16]. Hypoxia has been confirmed to be closely
related to the genetic instability of tumor cells, and plays important roles in the occurrence and development of tumors[4-6]. However, the relationship between hypoxia and abnormal DNA methylation of tumor cells during the development of LUAD remains to be further explored.

Materials and methods

Data sets

The clinical information, gene expression and DNA methylation profiles of 533 LUAD patients in The Cancer Genome Atlas (TCGA) database (https://tcga-data.nci.nih.gov/tcga/) were downloaded. Hypoxia score (HS) was analyzed according to the hypoxia system-related metagene clusters and a gene set variation analysis (GSVA) [17, 18]. One-Way ANOVA analysis was used to assess the differences of HS in different smoking states or different tumor stages.

Identification of differentially expressed genes (DEGs) and differentially methylated genes (DMGs)

P<0.05 and |log2(fold change)|>2.0 were considered as the cutoff values for DMGs and DEGs identification. The pheatmap package of R software was used to generate heatmap. Distribution analysis of differentially methylated probes (DMPs) was performed according to the previous reference[19].

Hypomethylated-upregulated genes were identified by overlapping the hypomethylated genes and upregulated genes. Hypermethylated-downregulated genes were identified by overlapping the hypermethylated genes and downregulated genes.

Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), protein–protein interaction (PPI) network and motif enrichment analysis

GO and KEGG analysis of the aberrantly methylated DEGs were carried out using clusterProfile package, with P<0.05 as the screening standard. For PPI network analysis, the aberrantly methylated DEGs were analyzed by STRING database (version 11.0) (https://string-db.org/) , and then the results were screened by
Molecular Complex Detection (MCODE) in Cytoscape software ([http://www.cytoscape.org](http://www.cytoscape.org)) with default parameter. The 2-kb upstream region of FAM20C, MYLIP and COL7A1 promoters were further analyzed with Transcription factor Affinity Prediction (TRAP) Web Tools to identify enriched motifs[20].

Survival analysis

To analyze the effect of hypoxia on the prognosis, data in TCGA database were divided into HS-high group and HS-low group according to the hypoxia score, and Kaplan-Meier curves of overall survival (OS) and disease-free survival (DFS) were drawn using R software. In order to analyze the effects of genes expression on the patient's OS, Kaplan-Meier analysis was performed based on the data in TCGA database. Genes with significant differences of OS between the high-expression group and low-expression group were screened, and then the screened genes were verified using the data downloaded from Kaplan Meier-plotter database ([http://www.kmplot.com](http://www.kmplot.com)). Similarly, Kaplan-Meier curves were plotted based on the data of DNA methylation probes in TCGA database to analyze the effects of DNA methylation status on the prognosis. P < 0.05 was accepted as significant difference.

Cell culture and cell treatment

Human lung adenocarcinoma cell line, A549, was purchased from ATCC and cultured in DMEM medium (Gibco, Carlsbad, CA, USA) with 10% FBS (Gibco) at 37 °C with 5% CO₂. For hypoxia treatment, cells were cultured in tri-gas incubator (Thermo, MA, USA) consisting of 2% O₂, 5% CO₂ and 93% N₂ for 24 h. Then, the cells were treated with the DNA methylation inhibitor 5-Aza-2′-deoxycytidine (Aza) (10 μM, Sigma, USA).

Quantitative real-time PCR (qRT-PCR)

The total RNA of cells were extracted using TRIzol reagent (Invitrogen). PrimeScript RT reagent kit (Takara, Japan) and SYBR Premix Ex Taq II (Takara)
were applied for reverse transcription and qRT-PCR, respectively. GAPDH was selected as internal reference gene. The relative expression levels of mRNA were calculated using \(2^{-\Delta\Delta Ct}\) method. Primers used in this study were provided in Table 1.

Table 1 Primers used for qRT-PCR analysis.

| Genes   | Primer sequences (5’-3’)                                      |
|---------|----------------------------------------------------------------|
| FAM20C  | F: 5’- GCCGTGGACTCCTATCCTCCC-3’                                |
|         | R: 5’- GCCCGTAATTCTGGAAAGGTCA-3’                                |
| MYLIP   | F: 5’- GCAGGGCACTGGGAATCATAG-3’                                 |
|         | R: 5’- CGGTTCCTCAGGTATGCCAT-3’                                  |
| COL7A1  | F: 5’- TTACGCCGCTGACATTTGTT-3’                                  |
|         | R: 5’- ACCAGCCCTTCGAGAAAGC-3’                                  |
| GAPDH   | F: 5’- TGTGGGCATCAATGGATTTTG-3’                                 |
|         | R: 5’- ACACCATGTATTCCGGGTCAAT-3’                                |

Results

Relationship between hypoxia and smoking, cancer stage or prognosis

A total of 533 patients with LUAD were divided into HS-high group (n=247) and HS-low group (n=286) according to their HS values. As shown in Fig. 1B, the HS values of LUAD patients who reformed smoking (average HS=0.8), never-smoking (average HS=1.0) and smoking (average HS=1.16) increased significantly in turn. In addition, the average HS increased with the increase of cancer stages (P<0.0001) (Fig. 1C). Then, the effects of hypoxia on prognosis were analyzed. Kaplan-Meier survival curves suggested that both OS and DFS of HS-high group were notably lower than those of HS-low group (Fig. 1C and 1D). Taken together, these results revealed that smoking status and cancer stages were significantly associated with LUAD hypoxia, and patients with a higher degree of hypoxia had a poorer outcome.
Aberrantly methylated DEGs in HS-high group compared with HS-low group

To explore the effect of hypoxia degree on DNA methylation status of LUAD cells, a total of 12176 DMGs were identified according to P<0.05 and |log2(fold change)| >2.0. Subsequently, the DMPs were classified according to the genomic feature (Fig. 2A). The DMPs mainly located in gene body (39.92%) and noncoding intergenic region (IGR, 21.38%) (Fig. 2A). Remarkably, the distribution frequency of DMPs in open sea was the highest in IGR (Fig. 2A). Five thousand and sixty five DEGs were identified, including 2413 upregulated genes and 2652 downregulated genes (Fig. 2B).

Venn diagram showed that there were 740 hypomethylated-upregulated genes were overlapped between hypomethylated DMGs (n=6520) and upregulated DEGs (n=2413) (Fig. 3A). A total of 1063 hypermethylated-downregulated genes were overlapped between hypermethylated DMGs (n=5656) and downregulated DEGs (n=2652) (Fig. 3B). Collectively, a total of 1803 aberrantly methylated DEGs (including 740 hypomethylated-upregulated genes and 1063 hypermethylated-downregulated genes) were identified in HS-high group compared with HS-low group.

GO term and KEGG pathway analysis

To further investigate the effects of DNA methylation status on the above overlapped genes, all of the 1803 aberrantly methylated DEGs were used for GO and KEGG analysis. The top 10 significant GO terms were presented in Fig. 4A. GO analysis showed that the aberrantly methylated DEGs were significantly enriched in response to peptide, extracellular structure organization and small GTPase mediated signal transduction. Furthermore, KEGG analysis suggested that the metabolic pathways associated with hypoxia stress, angiogenesis and cancer progression were enriched such as PI3K-Akt signaling pathway and HIF-1 signaling pathway (Fig. 4B).

PPI analysis
All of the 1803 aberrantly methylated DEGs were analyzed by STRING database and screened by Cytoscape software. The PPI network consisted of 32 modules, containing a total of 1692 nodes and 14422 edges. The top 2 significant modules were shown in Fig. 5. There were 45 nodes and 491 edges in the module 1 (Fig. 5A). A total of 407 edges and 50 nodes formed the module 2 (Fig. 5B).

**Survival analysis of the enriched genes in module 1 and module 2 of PPI network**

To further identify the key genes related to hypoxia in LUAD, survival analysis of the 95 enriched genes (including 45 genes in module 1 and 50 genes in module 2) in TCGA database was performed. The data suggested that the expression levels of UBE2D1, FAM20C, MYLIP and COL7A1 were significantly associated with the prognosis of LUAD (Fig. 6A-6D). Subsequently, the survival analysis of UBE2D1, FAM20C, MYLIP and COL7A1 were validated in the Kaplan Meier-plotter database. High expression levels of FAM20C and COL7A1 were significantly associated with poor prognosis (Fig. 6F and 6H), while patients with high expression level of MYLIP had a better prognosis (Fig. 6G). The above results were consistent with the results of TCGA database. However, the survival analysis of data in Kaplan Meier-plotter database showed that UBE2D1 expression had no significant effect on the prognosis of LUAD (Fig. 6E). Finally, data of methylation probes of FAM20C, MYLIP and COL7A1 in TCGA database was downloaded. Hypomethylation of FAM20C (Fig. 7A-7C) and COL7A1 (Fig. 7E-7F) were associated with poor outcome, while the hypomethylation of MYLIP (Fig. 7D) was associated with better survival. To verify FAM20C, MYLIP and COL7A1 were the hypoxia-related DNA methylation-driven genes, A549 cells were divided into normoxic, hypoxic and hypoxic+Aza groups. As shown in figure 8, hypoxia treatment significantly increased FAM20C and COL7A1 expression, and DNA methylation inhibitor Aza treatment further promote the expression of FAM20C and COL7A1. MYLIP was downregulated in hypoxic group compared with normoxic group, while Aza treatment reversed this effect (Fig. 8). Taken together, FAM20C, MYLIP and COL7A1 were identified as the key potential genes affecting hypoxia-associated LUAD progression.
FAM20C, MYLIP and COL7A1 potentially targeted by NF-κB

As transcription factors hypoxia-inducible factor-1α (HIF-1α) and nuclear factor-κB (NF-κB) play a key role in regulation hypoxia and tumorigenesis, we analyzed the 2-kb upstream region of FAM20C, MYLIP and COL7A1 promoters for the HIF-1α and NF-κB-binding sequence. Indeed, FAM20C, MYLIP and COL7A1 are potentially regulated by NF-κB. However, we did not find a binding site for HIF-1α (Fig. 9). These results suggest that NF-κB may directly transactivate the expression of FAM20C, MYLIP and COL7A1 during hypoxia-associated LUAD progression.

Discussion

The hypoxic microenvironment is an important feature of solid tumors[4-6]. In this study, we demonstrated a positive correlation between hypoxia degree and tumor stages in LUAD, and patients with high degree of hypoxia had poor prognosis. Under hypoxic conditions, tumor cells secrete a variety of angiogenic factors to promote the abnormal angiogenesis. In addition, hypoxia improves the invasion and metastasis ability of tumor cells, increases the malignancy of tumor, and further results in insensitivity of tumor cells to chemotherapy drugs or radiation therapy[7, 8]. Thus, the hypoxic microenvironment is an important factor in cancer poor prognosis.

Tumor development is often accompanied by DNA methylation imbalance. The inactivation of tumor suppressor genes caused by abnormal hypermethylation is particularly important[21]. Studies have shown that hypoxia is one of the important driving forces for DNA methylation imbalance in tumor cells, and interacts with epigenetic regulation mechanisms to promote tumor development[22, 23]. In this study, a total of 12176 DMGs were identified by comparing DNA methylation status in HS-high and HS-low groups. The results reminded that hypoxia can cause extensive methylation imbalance in tumor cells. This phenomenon may be related to the downregulation of DNA methyltransferases, and the regulation of histone modification and DNA methylation patterns[24, 25].

The epigenetic regulation can further promote the hypoxic adaptive response, help tumor cells acquire more malignant phenotypes, and escape the toxic effects of
radiotherapy and chemotherapy[26, 27]. This study explored the key genes involved in the development of hypoxia-associated LUAD, and their interactions with other factors. We identified 1803 hypoxia-related aberrantly methylated DEGs, and then performed annotation and functional analysis of these genes. We found that hypoxia-related aberrantly methylated DEGs were significantly involved in hypoxia stress, angiogenesis, and cancer progression related biological processes. The skeletal system is one of the most common sites of lung cancer metastasis[28, 29]. Ossification is associated with LUAD bone metastasis, and the hypoxic microenvironment plays important roles in this process[30, 31]. HIFs is an important class of oxygen-dependent transcriptional activators. The expression of HIFs can promote the adaptation of tumor cells to hypoxia microenvironment[9]. Moreover, HIFs can further regulate a variety of genes related to invasion and metastasis of tumor cells[32, 33]. The high expression of HIFs can be considered as a high risk factor of metastasis. Other biological pathways enriched in this study, such as proteoglycans in cancer, PI3K-Akt signaling pathway, extracellular structure organization and small GTPase mediated signal transduction, were also closely related to tumor progression and hypoxic microenvironment formation. These results indicated that hypoxia can cause imbalance of DNA methylation in tumor cells, and further affect tumor progression and metastasis.

To further screen the key genes in the hypoxia-related LUAD progression, we constructed a PPI network and performed prognostic analysis. FAM20C, MYLIP and COL7A1 were identified as the key potential genes affecting hypoxia-related LUAD progression. FAM20C is an intracellular casein kinase that phosphorylates hundreds of secreted proteins to regulate a variety of physiological and pathological processes, including skeletal development and blood phosphorus metabolism. Studies have shown that FAM20C regulates the redox homeostasis of the endoplasmic reticulum by phosphorylating the endoplasmic reticulum thiol oxidase Ero1a during hypoxic stress[34]. However, the relationship between FAM20C and LUAD has not been reported. In this study, we found that hypoxia in LUAD cells inhibited DNA methylation of FAM20C gene, promoted FAM20C gene expression, and further led to
deterioration of LUAD. The expression levels and methylation status of FAM20C can be used as markers for judging the prognosis of LUAD. Myosin-regulated light chain interacting protein (MYLIP), also known as ubiquitin-protein ligase, regulates the post-transcriptional diversity of low-density lipoprotein (LDL) receptors. Studies have confirmed that MYLIP inhibits the metastasis and progression of breast cancer[35]. Our study indicated that MYLIP was a tumor suppressor during the progression of LUAD, and hypoxia promoted DNA methylation of MYLIP. COL7A1 encoding type VII collagen. Collagen changes in the tumor microenvironment are mainly manifested in nascent collagen, density, direction, length, cross-linking and so on. These changes affect tumor cell metabolism, macromolecular transport, gene expression, angiogenesis, and also affect tumor invasion and metastasis by regulating epithelial mesenchymal transition, immunity and stromal cells[36]. Our study confirmed that COL7A1 was an oncogene of LUAD and was associated with poor prognosis of LUAD. Hypoxia led to hypomethylation of COL7A1.

Hypoxic microenvironment will change the metabolism of tumor cells, induce adaptive changes in cell metabolism, and regulate complex cellular signaling pathways such as HIF-1α and NF-κB[37]. Among them, NF-κB participates in inflammatory response and regulates cell proliferation and survival[38-40]. At the same time, NF-κB can also regulate the expression of key mediators of endothelial cell survival and angiogenesis such as AKT and VEGF[41, 42]. Our study showed that NF-κB may directly transactivates the expression of FAM20C, MYLIP and COL7A1 during hypoxia-associated LUAD progression.

In conclusion, we performed a genome-wide comparative analysis on the hypoxia-related DNA methylation profiles of LUAD based on TCGA database. The results reminded that hypoxia in LUAD tumor cells led to changes in DNA methylation patterns. FAM20C, MYLIP and COL7A1 were identified as the hypoxia-related key genes in LUAD progression, which were regulated by DNA methylation. In-depth study of the relationship between hypoxia and DNA methylation is helpful to clarify the mechanism of tumorigenesis, and provide new ideas for LUAD treatment.
Data Availability
All relevant data are contained within the paper. Additional information can be obtained by contacting Dr. Zhe Liu (zheliu_lza@163.com).

Authors’ contributions
Hongxia Li acquired the data and created a draft of the manuscript; Li Tong performed the statistical analysis and analyzed the results; Hong Tao revised the manuscript; Zhe Liu conducted thesis selection and approved the final version of the manuscript. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding
This study was supported by no funding.

Conflict of interest
The authors declare that they have no conflicts of interest.
References

1. Rafei, H., et al., *Immune-based Therapies for Non-small Cell Lung Cancer*. Anticancer Res, 2017. 37(2): p. 377-387.

2. Seigneurin, A., et al., *A systematic review of the characteristics associated with recall rates, detection rates and positive predictive values of computed tomography screening for lung cancer*. Ann Oncol, 2014. 25(4): p. 781-91.

3. Tao, L., et al., *Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway*. Sci Rep, 2016. 6: p. 38408.

4. Parks, S.K., Y. Cormerais, and J. Pouyssegur, *Hypoxia and cellular metabolism in tumour pathophysiology*. J Physiol, 2017. 595(8): p. 2439-2450.

5. Liu, Y., et al., *Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9*. J Hepatol, 2015. 63(1): p. 114-21.

6. Gilkes, D.M., G.L. Semenza, and D. Wirtz, *Hypoxia and the extracellular matrix: drivers of tumour metastasis*. Nat Rev Cancer, 2014. 14(6): p. 430-9.

7. Meng, W., et al., *Exosome-orchestrated hypoxic tumor microenvironment*. Mol Cancer, 2019. 18(1): p. 57.

8. Schito, L., *Bridging angiogenesis and immune evasion in the hypoxic tumor microenvironment*. Am J Physiol Regul Integr Comp Physiol, 2018. 315(6): p. R1072-R1084.

9. Huang, Y., D. Lin, and C.M. Taniguchi, *Hypoxia inducible factor (HIF) in the tumor
10. Horsman, M.R. and J. Overgaard, *The impact of hypoxia and its modification of the outcome of radiotherapy*. J Radiat Res, 2016. **57 Suppl 1**: p. i90-i98.

11. Toh, T.B., J.J. Lim, and E.K. Chow, *Epigenetics in cancer stem cells*. Mol Cancer, 2017. **16**(1): p. 29.

12. Nakaoka, T., Y. Saito, and H. Saito, *Aberrant DNA Methylation as a Biomarker and a Therapeutic Target of Cholangiocarcinoma*. Int J Mol Sci, 2017. **18**(6).

13. Kelly, A.D. and J.J. Issa, *The promise of epigenetic therapy: reprogramming the cancer epigenome*. Curr Opin Genet Dev, 2017. **42**: p. 68-77.

14. Chiappinelli, K.B., et al., *Combining Epigenetic and Immunotherapy to Combat Cancer*. Cancer Res, 2016. **76**(7): p. 1683-9.

15. Jones, P.A., et al., *Epigenetic therapy in immune-oncology*. Nat Rev Cancer, 2019. **19**(3): p. 151-161.

16. Long, M.D., D.J. Smiraglia, and M.J. Campbell, *The Genomic Impact of DNA CpG Methylation on Gene Expression; Relationships in Prostate Cancer*. Biomolecules, 2017. **7**(1).

17. Brooks, J.M., et al., *Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer*. Clin Cancer Res, 2019. **25**(17): p. 5315-5328.

18. Hanzelmann, S., R. Castelo, and J. Guinney, *GSVA: gene set variation analysis for microarray and RNA-seq data*. BMC Bioinformatics, 2013. **14**: p. 7.

19. Zhu, L., et al., *Genome-wide DNA methylation profiling of primary colorectal laterally
spreading tumors identifies disease-specific epimutations on common pathways. Int J Cancer, 2018. 143(10): p. 2488-2498.

20. Thomas-Chollier, M., et al., *Transcription factor binding predictions using TRAP for the analysis of ChIP-seq data and regulatory SNPs*. Nat Protoc, 2011. 6(12): p. 1860-9.

21. Zhang, M.W., et al., *DNA methylation in the tumor microenvironment*. J Zhejiang Univ Sci B, 2017. 18(5): p. 365-372.

22. Yeo, C.D., et al., *The role of hypoxia on the acquisition of epithelial-mesenchymal transition and cancer stemness: a possible link to epigenetic regulation*. Korean J Intern Med, 2017. 32(4): p. 589-599.

23. Batie, M., et al., *Hypoxia induces rapid changes to histone methylation and reprograms chromatin*. Science, 2019. 363(6432): p. 1222-1226.

24. Hervouet, E., et al., *Specific or not specific recruitment of DNMTs for DNA methylation, an epigenetic dilemma*. Clin Epigenetics, 2018. 10: p. 17.

25. Esteller, M., *Cancer epigenomics: DNA methylomes and histone-modification maps*. Nat Rev Genet, 2007. 8(4): p. 286-98.

26. Prasad, P., et al., *Hypoxia-Mediated Epigenetic Regulation of Stemness in Brain Tumor Cells*. Stem Cells, 2017. 35(6): p. 1468-1478.

27. Casciello, F. and J.S. Lee, *G9a in hypoxia: Linking tumor hypoxia and epigenetic regulation*. Cell Cycle, 2017. 16(21): p. 2001-2002.

28. Zhang, L. and Z. Gong, *Clinical Characteristics and Prognostic Factors in Bone Metastases from Lung Cancer*. Med Sci Monit, 2017. 23: p. 4087-4094.

29. Lang, J., et al., *Bone turnover markers and novel biomarkers in lung cancer bone
metastases. Biomarkers, 2018. 23(6): p. 518-526.

30. Wang, H., et al., Cellular Hypoxia Promotes Heterotopic Ossification by Amplifying BMP Signaling. J Bone Miner Res, 2016. 31(9): p. 1652-65.

31. Johnson, R.W., M.E. Sowder, and A.J. Giaccia, Hypoxia and Bone Metastatic Disease. Curr Osteoporos Rep, 2017. 15(4): p. 231-238.

32. Zhang, Y., et al., HIF-1alpha Promotes Breast Cancer Cell MCF-7 Proliferation and Invasion Through Regulating miR-210. Cancer Biother Radiopharm, 2017. 32(8): p. 297-301.

33. Lin, M.C., et al., GATA3 interacts with and stabilizes HIF-1alpha to enhance cancer cell invasiveness. Oncogene, 2017. 36(30): p. 4243-4252.

34. Zhang, J., et al., Secretory kinase Fam20C tunes endoplasmic reticulum redox state via phosphorylation of Ero1alpha. EMBO J, 2018. 37(14).

35. Zhao, L., et al., miR-19b promotes breast cancer metastasis through targeting MYLIP and its related cell adhesion molecules. Oncotarget, 2017. 8(38): p. 64330-64343.

36. Peng, D.H., et al., ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis. Oncogene, 2017. 36(14): p. 1925-1938.

37. Filippi, I., F. Carraro, and A. Naldini, Interleukin-1beta Affects MDAMB231 Breast Cancer Cell Migration under Hypoxia: Role of HIF-1alpha and NFkappaB Transcription Factors. Mediators Inflamm, 2015. 2015: p. 789414.

38. Ahn, K.S., et al., Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear
factor-kappaB ligand through modulation of NF-kappaB pathway. Int J Cancer, 2008. 123(8): p. 1733-40.

39. Manna, S.K., et al., Morin (3,5,7,2',4'-Pentahydroxyflavone) abolishes nuclear factor-kappaB activation induced by various carcinogens and inflammatory stimuli, leading to suppression of nuclear factor-kappaB-regulated gene expression and up-regulation of apoptosis. Clin Cancer Res, 2007. 13(7): p. 2290-7.

40. Ahn, K.S., G. Sethi, and B.B. Aggarwal, Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-kappaB pathway. Biochem Pharmacol, 2008. 75(4): p. 907-13.

41. Arsura, M. and L.G. Cavin, Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett, 2005. 229(2): p. 157-69.

42. Huh, J.I., et al., Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms. Oncogene, 2005. 24(5): p. 790-800.
Figure legends

**Figure 1** Relationship between hypoxia and smoking, cancer stage and prognosis. (A) 533 LUAD patients were divided into two groups, hypoxia score (HS)-high group (n=247) and HS-low group (n=286), according to their HS values. One-Way ANOVA analysis was performed to evaluate the differences of HS in different smoking states or different tumor stages. (B) HS of LUAD patients who reformed smoking, no-smoking and smoking. (C) HS of different cancer stages. (D) Analysis of overall survival (OS) based on HS. HS-high group, n=245; HS-low group, n=244. (E) Analysis of disease-free survival (DFS) based on HS. HS-high group, n=228; HS-low group, n=229.

**Figure 2** Analysis of DMGs and DEGs in HS-high group compared with HS-low group. (A) Distribution of the DMPs with different genomic feature. (B) Heatmap of DEGs between HS-high group and HS-low group. P<0.05 and |log2 (fold change)|>2.0 were selected as the cutoff values.

**Figure 3** Overlapping relationship between DEGs and DMGs. (A) Venn diagram of hypomethylation and upregulated genes. (B) Venn diagram of hypermethylation and downregulated genes.

**Figure 4** GO term and KEGG pathway analysis for the aberrantly methylated DEGs. (A) The top 10 significant GO terms. (B) The top 10 significant KEGG pathways.

**Figure 5** The top 2 significant modules in PPI network. Red nodes: upregulated gene in HS-high group vs. HS-low group; Green nodes: downregulated gene in HS-high group vs. HS-low group.

**Figure 6** Survival analysis of UBE2D1, FAM20C, MYLIP and COL7A1 expression. (A-D) UBE2D1 (A), FAM20C (B), MYLIP (C) and COL7A1 (D) in TCGA database. (E-H) UBE2D1 (E), FAM20C (F), MYLIP (G) and COL7A1 (H) in Kaplan Meier-plotter database.

**Figure 7** DNA methylation status of FAM20C, MYLIP and COL7A1 associated with overall survival. (A-C) Methylation probes of FAM20C. (D) Methylation probe of MYLIP. (E-F) Methylation probes of COL7A1.
**Figure 8** Relative expression levels of FAM20C, MYLIP and COL7A1 in normoxic, hypoxic and hypoxic+Aza groups. *P<0.05, hypoxic group vs. normoxic group. #P<0.05, hypoxic+Aza group vs. hypoxic group.

**Figure 9** FAM20C (A), MYLIP (B) and COL7A1 (C) potentially targeted by NF-κB.
A

response to peptide
extracellular structure organization
small GTPase mediated signal transduction
extracellular matrix organization
ossification
cellular response to peptide
cell-substrate adhesion
cellular response to insulin stimulus
formation of primary germ layer
cell-substrate junction assembly

GeneRatio

5.0e-08
1.0e-07
1.5e-07

Count

B

Parathyroid hormone synthesis, secretion and action
Focal adhesion
Human papillomavirus infection
AGE-RAGE signaling pathway in diabetic complications
PI3K-Akt signaling pathway
ECM-receptor interaction
Proteoglycans in cancer
Human cytomegalovirus infection
Regulation of actin cytoskeleton
HIF-1 signaling pathway

p.adjust

1e-04
2e-04
3e-04
4e-04
